There are still some issues that are going to need to be worked out with the FDA, but some major hurdles have been crossed.

Half a dozen will jump in fairly quickly.

Doug and I had a great match.

They have a more complicated structure and require more complicated processing. Our role is to better understand the and transfer the technology to industry.

It's been a long frustrating case, ... We would really like to get some help from the public.

With their amount of cash, if Pfizer couldn't get growth organically, I figured they would buy their growth through more acquisitions.

The PTA is supportive too.

We wanted to try to get all the way to the clubhouse and settle it on the last hole and we got there.

Our hope (in this case) is we will get a cold hit, ... It's important that we put this case to rest.